China Orders Pfizer And Wyeth To Divest Certain Operations As Condition To Merger Approval
This article was originally published in PharmAsia News
Executive Summary
BEIJING - China's Ministry of Commerce has ordered Pfizer and Wyeth to divest themselves of certain business operations here in order to gain government approval for their $68-billion merger
You may also be interested in...
Pfizer Sells Nutrition Portfolio To Nestle For Nearly $12B, Widening Nestle’s Reach In Emerging Markets
Pfizer’s price of $11.85 billion for selling its pediatric nutritionals business to Nestle came in at the upper end of what most analysts expected. It plans to use the cash it expects to receive – nearly $9 billion – mostly for share repurchases and ‘”tuck-in” M&A.
Pfizer Sells Nutrition Portfolio To Nestle For Nearly $12B, Widening Nestle’s Reach In Emerging Markets
Pfizer’s price of $11.85 billion for selling its pediatric nutritionals business to Nestle came in at the upper end of what most analysts expected. It plans to use the cash it expects to receive – nearly $9 billion – mostly for share repurchases and ‘”tuck-in” M&A.
Hong Kong's New Competition Law Could Have Impact On Drug Firms Around The World
BEIJING - Hong Kong's Legislative Council has begun reviewing a new competition bill that, depending on the contours of the law that is ultimately approved, could have a significant impact on the healthcare sector and life science-based enterprises, according to two lawyers who have closely studied the bill